十六位血液惡性腫瘤及再生不良性貧血患者在接受相同劑量之放射線及化學治療後,接受骨髓移植,其中八位病人並接受人類顆粒球細胞群落刺激因子(rhG-CSF)之治療,而另外八位則為對照組。結果顯示可知rhG-CSF能有效縮短骨髓移植後顆粒球回升之速度、發燒時間,而降低抗生素之使用天數及醫療費用。而且其副作用小,安全性高,臨床上值得推薦。
Sixteen patients with severe aplastic anemia or various types of hematological malignancy underwent allogenic bone marrow transplantation (Allogenic BMT) accompanied with and without recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy. All patients received the same conditioning regimen including total body irradiation and cyclophosphamide chemotherapy. Eight of them received rhG-CSF (400μg/m^2/day) after BMT. The duration of neutropenia,and fever were significantly shortened in the patients with rhG-CSF treatment than those without rhG-CSF treatment (p<0.05). All the patients treated with rhG-CSF tolerated very well to the administration of rhG-CSF. The benefits of rhG-CSF are obvious.